Back to Search
Start Over
Lactococcus lactis KA-FF 1-4 reduces vancomycin-resistant enterococci and impacts the human gut microbiome.
- Source :
-
3 Biotech [3 Biotech] 2020 Jul; Vol. 10 (7), pp. 295. Date of Electronic Publication: 2020 Jun 08. - Publication Year :
- 2020
-
Abstract
- Probiotic is an alternative method to treat intestinal infection disease caused by antibiotic-resistant bacteria. In this study, Lactococcus lactis KA-FF 1-4 demonstrated to have the potential to inhibit the growth of Vancomycin-resistant enterococci (VRE) by producing anti-microbial substance. In co-culture, L. lactis KA-FF 1-4 (10 <superscript>8</superscript>  CFU/mL) inhibited the growth of VRE from 10 <superscript>3</superscript> -10 <superscript>4</superscript>  CFU/mL to zero after 6 h of exposure. However, in a gut model contained human gut microbiota, this anti-VRE activity of L. lactis KA-FF 1-4 was reduced to only 3.59-6.12%. The unexpected difference in efficacy between the experimental models could be explained by the fact that the growth of L. lactis KA-FF 1-4 was stable in the gut model. Leaving aside these limitations, we observed that adding L. lactis KA-FF 1-4 into the human gut model containing VRE was able to enhance microbial richness and diversity. Specifically, a higher abundance of beneficial microbes from the group of Bifidobacterium spp. and Bacteroides fragilis . L. lactis KA-FF 1-4 also enhanced the abundance of Parabacteroides , Lactococcus , and Fusobacterium and promoted the production of lactic acid in the gut model. However, these effects were not observed in the gut model without L. lactis KA-FF 1-4. Even though this study could not demonstrate a significant anti-VRE effect of the L. lactis KA-FF 1-4 in a gut model, our results still offer evidence that L. lactis KA-FF 1-4 could positively modulate the gut microbiota by promoting the growth of beneficial microbes and their metabolite. L. lactis KA-FF 1-4 has probiotic properties to fight against VRE infection, therefore further investigation in animal model is needed.<br />Competing Interests: Conflict of interestOn behalf of all authors, the corresponding author states that there is no conflict of interest.<br /> (© King Abdulaziz City for Science and Technology 2020.)
Details
- Language :
- English
- ISSN :
- 2190-572X
- Volume :
- 10
- Issue :
- 7
- Database :
- MEDLINE
- Journal :
- 3 Biotech
- Publication Type :
- Academic Journal
- Accession number :
- 32550112
- Full Text :
- https://doi.org/10.1007/s13205-020-02282-6